Pacritinib Clinical Trials (2026): 49 Studies for Primary Myelofibrosis & Myelofibrosis
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
49 Pacritinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 34 indications (including Primary Myelofibrosis & Myelofibrosis) and 2,811 total planned enrollment. 3 Phase 3 Pacritinib trials and 21 Phase 2 are listed. 19 Pacritinib clinical trials are actively recruiting at 36 U.S. sites across 17 states. Most recent activity: NCT06303193 (Jan 2035).
Where to Participate: All Pacritinib Trial Sites in the U.S. (36 sites across 17 states)
Every actively recruiting Pacritinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | Mayo Clinic - Scottsdale | Scottsdale85259 | NCT06782373 | Map |
| CA | City of Hope | Duarte91010 | NCT04858256 | Map |
| CA | City of Hope - Duarte Main Site | Duarte91010 | NCT05980806 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT06675123 | Map |
| FL | University of Miami | Miami33101 | NCT05531786 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT07033598 | Map |
| GA | Winship Cancer Institute at Emory | Atlanta30322 | NCT07033598 | Map |
| KS | The University of Kansas Cancer Center | Fairway66204 | NCT06414681 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT05531786 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT06052618 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT06303193 | Map |
| MD | Maryland Oncology Hematology - Independent of SCRI/ US Oncology | Columbia21044 | NCT05980806 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT06782373 | Map |
| MA | Dana Farber Cancer Institute | Boston02115 | NCT06986174 | Map |
| MI | University of Michigan Rogel Cancer Center | Ann Arbor48109 | NCT04858256 | Map |
| MN | Mayo Clinic - Rochester | Rochester55905 | NCT06782373 | Map |
| MN | Mayo Clinic Rochester | Rochester55905 | NCT07033598 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT06538181 | Map |
| NY | NYU Langone Health | New York10016 | NCT06782373 | Map |
| NY | The Mount Sinai Hospital | New York10029 | NCT06159491 | Map |
| NY | Weill Cornell Medicine NewYork-Presbyterian | New York10021 | NCT05980806 | Map |
| NC | Duke Cancer Institute | Durham27710 | NCT04858256 | Map |
| NC | Duke University | Durham27705 | NCT05980806 | Map |
| OH | Cleveland Clinic | Cleveland44195 | NCT05980806 | Map |
| OH | Cleveland Clinic - Cleveland | Cleveland44195 | NCT06782373 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43202 | NCT04858256 | Map |
| OH | The James Cancer Hospital and Solove Research Institute | Columbus43210 | NCT06782373 | Map |
| PA | Fox Chase Cancer Center - Philadelphia | Philadelphia19111-2497 | NCT06218628 | Map |
| TX | MD Anderson | Houston77030 | NCT05980806 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT07033598 | Map |
| TX | UT MD Anderson Cancer Center | Houston77030 | NCT06782373 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112 | NCT05980806 | Map |
| UT | University of Utah Healthcare | Salt Lake City84132 | NCT06782373 | Map |
| WA | Fred Hutch/University of Washington Cancer Consortium | Seattle98109 | NCT04282187 | Map |
| WA | Fred Hutch/University of Washington Cancer Consortium | Seattle98109 | NCT07148947 | Map |
| WA | Fred Hutchinson Cancer Center | Seattle98109 | NCT06782373 | Map |
Pacritinib clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | withdrawn | not yet recruiting | Total |
|---|---|---|---|---|---|---|---|
| Early P1 | 1 | 1 | |||||
| P1 | 3 | 10 | 2 | 1 | 16 | ||
| P1/P2 | 3 | 1 | 1 | 1 | 1 | 1 | 8 |
| P2 | 9 | 1 | 1 | 7 | 1 | 2 | 21 |
| P3 | 1 | 2 | 3 |
Recruiting Pacritinib clinical trials (19)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06303193 | Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms | P1/P2 | Myelodysplastic Syndromes | 160 | Jun 2026 |
| NCT06052618 | KSHVPhase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS) | P2 | KSHV Inflammatory Cytokine Syndrome (KICS) | 75 | Mar 2025 |
| NCT06986174 | A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia | P2 | Waldenström Macroglobulinemia | 30 | Nov 2025 |
| NCT07226713 | POSTPONEPacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors | P2 | Prostate Cancer | 32 | Jul 2026 |
| NCT06218628 | Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition | P1 | Primary Myelofibrosis | 24 | Apr 2024 |
| NCT07447817 | Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias | P2 | Myelofibrosis | 26 | May 2026 |
| NCT06538181 | VEXASPacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome | P1 | E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome | 15 | Feb 2025 |
| NCT07148947 | Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms | P2 | Accelerated Phase Myeloproliferative Neoplasm | 27 | Mar 2026 |
| NCT07033598 | PROSPERAPacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia | P2 | Leukemia, Myelomonocytic, Chronic | 66 | Jan 2026 |
| NCT04858256 | Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms | P2 | T-Cell Neoplasm | 100 | Mar 2023 |
| NCT05980806 | SENTRY-2A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia | P2 | Myelofibrosis | 58 | Apr 2024 |
| NCT07394153 | PACRIMYELPacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia | P2 | Myelofibrosis，MF | 30 | Apr 2026 |
| NCT06782373 | PAXISA Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) | P2 | VEXAS | 78 | May 2025 |
| NCT06675123 | Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma | P1 | Recurrent Mantle Cell Lymphoma | 10 | Jun 2026 |
| NCT06159491 | Pacritinib in CMML | P1/P2 | Chronic Myelomonocytic Leukemia | 26 | Sep 2024 |
| NCT05531786 | HSCTPhase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) | P1/P2 | Graft vs Host Disease | 50 | Mar 2023 |
| NCT07387354 | MDSPacritinib With Aza for Upfront Myelodysplastic Syndrome | P1/P2 | Myelodysplastic Syndromes | 25 | Jul 2026 |
| NCT06414681 | Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined | Early P1 | Myelofibrosis，MF | 20 | Aug 2025 |
| NCT04282187 | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | P2 | Acute Myeloid Leukemia | 25 | Mar 2020 |
Pacritinib clinical trials by indication
Primary Myelofibrosis (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06218628 | — | P1 | recruiting | Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition |
| NCT03165734 | PACIFICA | P3 | active not recruiting | A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis |
| NCT02584777 | — | P2 | withdrawn | A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis |
| NCT04884191 | — | P2 | completed | Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib |
| NCT02055781 | PAC326 | P3 | terminated | Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia |
| NCT01773187 | — | P3 | terminated | Pacritinib Versus Best Available Therapy to Treat Myelofibrosis |
Myelofibrosis (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07447817 | — | P2 | not yet recruiting | Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias |
| NCT05980806 | SENTRY-2 | P2 | recruiting | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia |
| NCT03645824 | HOVON134MF | P2 | active not recruiting | Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) |
| NCT02807077 | — | P1 | completed | PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects |
| NCT02765724 | — | P1 | completed | Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects |
Prostate Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07226713 | POSTPONE | P2 | not yet recruiting | Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors |
| NCT04635059 | BLAST | P2 | terminated | Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer |
Myelodysplastic Syndromes (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06303193 | — | P1/P2 | recruiting | Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms |
| NCT07387354 | MDS | P1/P2 | not yet recruiting | Pacritinib With Aza for Upfront Myelodysplastic Syndrome |
Myelofibrosis，MF (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07394153 | PACRIMYEL | P2 | recruiting | Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia |
| NCT06414681 | — | Early P1 | recruiting | Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined |
Chronic Myelomonocytic Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06159491 | — | P1/P2 | recruiting | Pacritinib in CMML |
| NCT02564536 | MPN | P1 | withdrawn | Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) |
Healthy (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02823171 | — | P1 | completed | To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects |
| NCT02803762 | — | P1 | completed | Investigate Absorption, Metabolism, Excretion, and Mass Balance of Pacritinib |
Healthy Subjects (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02807116 | — | P1 | completed | Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects |
| NCT02807207 | — | P1 | completed | To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects |
Recurrent Mantle Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06675123 | — | P1 | recruiting | Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma |
Accelerated Phase Myeloproliferative Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07148947 | — | P2 | recruiting | Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms |
Leukemia, Myelomonocytic, Chronic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07033598 | PROSPERA | P2 | recruiting | Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia |
Waldenström Macroglobulinemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06986174 | — | P2 | recruiting | A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia |
VEXAS (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06782373 | PAXIS | P2 | recruiting | A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) |
KSHV Inflammatory Cytokine Syndrome (KICS) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06052618 | KSHV | P2 | recruiting | Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS) |
E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06538181 | VEXAS | P1 | recruiting | Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome |
Advanced Lung Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06516887 | — | P1/P2 | terminated | Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma |
T-Cell Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04858256 | — | P2 | recruiting | Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms |
Graft vs Host Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05531786 | HSCT | P1/P2 | recruiting | Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) |
Drug Interactions (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05657613 | — | P1 | completed | Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects |
Hepatic Impairment (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05552183 | — | P1 | completed | Study to Evaluate the Safety, Tolerability, and PK of Pacritinib |
Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04520269 | PAIR | P1/P2 | active not recruiting | A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR) |
COVID19 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04404361 | — | P2 | terminated | PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer |
Acute Myeloid Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04282187 | — | P2 | recruiting | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms |
Lymphoma, T-Cell, Cutaneous (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03601819 | — | P1 | terminated | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders |
Graft Vs Host Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02891603 | — | P1/P2 | completed | A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression |
Chronic Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02677948 | — | P1/P2 | withdrawn | Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
Recurrent Adult Acute Myeloid Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02323607 | — | P1 | completed | Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations |
Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02469415 | MDS | P2 | terminated | Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) |
Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02277093 | — | P2 | terminated | Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer |
Acute Myeloid Leukemia (AML) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02532010 | Pacritinib | P2 | terminated | Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML |
Myeloproliferative Diseases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02410551 | MPN | P2 | terminated | Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) |
Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02342353 | EGFR | P1 | terminated | Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI) |
Drug Interaction Study (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02807051 | — | P1 | completed | To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects |
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01620216 | — | P2 | terminated | Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia |
Pacritinib pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| PACIFICA | NCT03165734 | P3 | active not recruiting | Primary Myelofibrosis | 407 | PMID 33232476 |
| PAC326 | NCT02055781 | P3 | terminated | Primary Myelofibrosis | 311 | PMID 34551507 |
| KSHV | NCT06052618 | P2 | recruiting | KSHV Inflammatory Cytokine Syndrome (KICS) | 75 | — |
| POSTPONE | NCT07226713 | P2 | not yet recruiting | Prostate Cancer | 32 | — |
| PROSPERA | NCT07033598 | P2 | recruiting | Leukemia, Myelomonocytic, Chronic | 66 | — |
| SENTRY-2 | NCT05980806 | P2 | recruiting | Myelofibrosis | 58 | — |
| PACRIMYEL | NCT07394153 | P2 | recruiting | Myelofibrosis，MF | 30 | — |
| PAXIS | NCT06782373 | P2 | recruiting | VEXAS | 78 | PMID 41753113 |
| HOVON134MF | NCT03645824 | P2 | active not recruiting | Myelofibrosis | 61 | — |
| BLAST | NCT04635059 | P2 | terminated | Prostate Cancer | 6 | — |
| Pacritinib | NCT02532010 | P2 | terminated | Acute Myeloid Leukemia (AML) | 13 | — |
| MDS | NCT02469415 | P2 | terminated | Leukemia | 3 | — |
| MPN | NCT02410551 | P2 | terminated | Myeloproliferative Diseases | 4 | — |
Terminated and withdrawn Pacritinib trials (15)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT06516887terminatedStudy of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma
- NCT04635059terminatedPacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer
- NCT04404361terminatedPRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer
- NCT02584777withdrawnA Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis
- NCT03601819terminatedPacritinib in Relapsed/Refractory Lymphoproliferative Disorders
- NCT02564536withdrawnPacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)
- NCT02677948withdrawnMulticenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- NCT02342353terminatedPacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)
- NCT02532010terminatedPacritinib Combined With Decitabine or Cytarabine in Older Patients With AML
- NCT02469415terminatedPacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
- NCT01620216terminatedTargeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
- NCT02410551terminatedPacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)
- NCT02277093terminatedPacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer
- NCT02055781terminatedPacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia
- NCT01773187terminatedPacritinib Versus Best Available Therapy to Treat Myelofibrosis
All Pacritinib trials (49)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06303193 | Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms | P1/P2 | recruiting | 160 | National Cancer Institute (NCI) | Jun 2026 | |
| NCT06052618 | KSHV | Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS) | P2 | recruiting | 75 | National Cancer Institute (NCI) | Mar 2025 |
| NCT06986174 | A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia | P2 | recruiting | 30 | Shayna Sarosiek, MD | Nov 2025 | |
| NCT07226713 | POSTPONE | Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors | P2 | not yet recruiting | 32 | Medical College of Wisconsin | Jul 2026 |
| NCT06218628 | Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition | P1 | recruiting | 24 | Fox Chase Cancer Center | Apr 2024 | |
| NCT07447817 | Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias | P2 | not yet recruiting | 26 | John Mascarenhas | May 2026 | |
| NCT06538181 | VEXAS | Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome | P1 | recruiting | 15 | Washington University School of Medicine | Feb 2025 |
| NCT07148947 | Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms | P2 | recruiting | 27 | University of Washington | Mar 2026 | |
| NCT07033598 | PROSPERA | Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia | P2 | recruiting | 66 | Theradex | Jan 2026 |
| NCT04858256 | Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms | P2 | recruiting | 100 | University of Michigan Rogel Cancer Center | Mar 2023 | |
| NCT05980806 | SENTRY-2 | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia | P2 | recruiting | 58 | Karyopharm Therapeutics Inc | Apr 2024 |
| NCT03165734 | PACIFICA | A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | P3 | active not recruiting | 407 | Swedish Orphan Biovitrum | Jun 2017 |
| NCT07394153 | PACRIMYEL | Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia | P2 | recruiting | 30 | Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas | Apr 2026 |
| NCT06782373 | PAXIS | A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) | P2 | recruiting | 78 | Swedish Orphan Biovitrum | May 2025 |
| NCT06675123 | Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma | P1 | recruiting | 10 | City of Hope Medical Center | Jun 2026 | |
| NCT06159491 | Pacritinib in CMML | P1/P2 | recruiting | 26 | Douglas Tremblay | Sep 2024 | |
| NCT05531786 | HSCT | Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) | P1/P2 | recruiting | 50 | National Cancer Institute (NCI) | Mar 2023 |
| NCT03645824 | HOVON134MF | Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) | P2 | active not recruiting | 61 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Jun 2018 |
| NCT07387354 | MDS | Pacritinib With Aza for Upfront Myelodysplastic Syndrome | P1/P2 | not yet recruiting | 25 | Thomas Jefferson University | Jul 2026 |
| NCT06414681 | Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined | Early P1 | recruiting | 20 | University of Kansas Medical Center | Aug 2025 | |
| NCT04282187 | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | P2 | recruiting | 25 | University of Washington | Mar 2020 | |
| NCT04520269 | PAIR | A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR) | P1/P2 | active not recruiting | 74 | National University Hospital, Singapore | Jul 2020 |
| NCT06516887 | Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma | P1/P2 | terminated | 4 | The University of Texas Health Science Center at San Antonio | Dec 2024 | |
| NCT04635059 | BLAST | Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer | P2 | terminated | 6 | Medical College of Wisconsin | Jun 2021 |
| NCT05552183 | Study to Evaluate the Safety, Tolerability, and PK of Pacritinib | P1 | completed | 29 | CTI BioPharma | Dec 2022 | |
| NCT05657613 | Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects | P1 | completed | 60 | CTI BioPharma | Jan 2023 | |
| NCT02891603 | A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression | P1/P2 | completed | 40 | H. Lee Moffitt Cancer Center and Research Institute | Jun 2017 | |
| NCT04404361 | PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer | P2 | terminated | 200 | CTI BioPharma | May 2020 | |
| NCT02584777 | A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis | P2 | withdrawn | 0 | Baxalta now part of Shire | Nov 2015 | |
| NCT03601819 | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | P1 | terminated | 4 | University of Michigan Rogel Cancer Center | May 2019 | |
| NCT02564536 | MPN | Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) | P1 | withdrawn | 0 | Washington University School of Medicine | Jun 2017 |
| NCT04884191 | Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib | P2 | completed | 165 | CTI BioPharma | Jul 2017 | |
| NCT02677948 | Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | P1/P2 | withdrawn | 0 | University of Michigan Rogel Cancer Center | Oct 2016 | |
| NCT02323607 | Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations | P1 | completed | 13 | Bhavana Bhatnagar | Jan 2016 | |
| NCT02342353 | EGFR | Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI) | P1 | terminated | 8 | Washington University School of Medicine | May 2015 |
| NCT02532010 | Pacritinib | Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML | P2 | terminated | 13 | Weill Medical College of Cornell University | Jun 2015 |
| NCT02469415 | MDS | Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) | P2 | terminated | 3 | M.D. Anderson Cancer Center | Sep 2015 |
| NCT01620216 | Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia | P2 | terminated | 12 | OHSU Knight Cancer Institute | May 2012 | |
| NCT02410551 | MPN | Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) | P2 | terminated | 4 | M.D. Anderson Cancer Center | Jun 2015 |
| NCT02277093 | Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer | P2 | terminated | 11 | Washington University School of Medicine | Sep 2015 | |
| NCT02055781 | PAC326 | Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia | P3 | terminated | 311 | CTI BioPharma | Feb 2014 |
| NCT01773187 | Pacritinib Versus Best Available Therapy to Treat Myelofibrosis | P3 | terminated | 327 | CTI BioPharma | Jan 2013 | |
| NCT02823171 | To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects | P1 | completed | 28 | CTI BioPharma | Aug 2015 | |
| NCT02807077 | PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects | P1 | completed | 40 | CTI BioPharma | Nov 2014 | |
| NCT02765724 | Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects | P1 | completed | 28 | CTI BioPharma | Jan 2015 | |
| NCT02807116 | Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects | P1 | completed | 18 | CTI BioPharma | Jan 2015 | |
| NCT02807207 | To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects | P1 | completed | 42 | CTI BioPharma | Oct 2014 | |
| NCT02807051 | To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects | P1 | completed | 20 | CTI BioPharma | Sep 2014 | |
| NCT02803762 | Investigate Absorption, Metabolism, Excretion, and Mass Balance of Pacritinib | P1 | completed | 6 | CTI BioPharma | Jul 2014 |
Pacritinib clinical trials: frequently asked questions
- How many Pacritinib clinical trials are there?
- 49 Pacritinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 16 are actively recruiting participants. 12 are marked completed.
- Are Pacritinib clinical trials recruiting in 2026?
- Yes — 16 Pacritinib trials are actively recruiting in 2026, with 36 U.S. sites across 17 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Pacritinib being studied for?
- Pacritinib is being studied for Primary Myelofibrosis, Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Chronic Myelomonocytic Leukemia and 74 more. The trials are grouped by indication on this page.
- What phase is Pacritinib in?
- Pacritinib clinical trials span 3 Phase 3, 21 Phase 2, 16 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Pacritinib clinical trials?
- The lead sponsor across the most Pacritinib trials is CTI BioPharma, with 25 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Pacritinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: